Current understanding and future prospects on Berberine for anticancer therapy.

Area of Science:

• Phytochemistry
• Molecular Biology
• Cancer Research

Background:

• Berberine (BBR) is a plant-derived metabolite with demonstrated anticancer potential.
• Extensive research explores BBR's cytotoxic effects in vitro and in vivo.
• Understanding BBR's molecular mechanisms is crucial for cancer therapy development.

Purpose of the Study:

• To review and summarize the diverse molecular targets and mechanisms underlying berberine's anticancer activity.
• To consolidate current knowledge on berberine's effects on cell cycle, proliferation, autophagy, invasion, and metastasis.
• To highlight berberine's role in regulating oncogenic pathways and carcinogenic enzymes.

Main Methods:

• Literature review of in vitro and in vivo studies on berberine's anticancer effects.
• Analysis of molecular targets including p53, cell cycle regulators, kinases, and transcription factors.
• Examination of berberine's impact on enzymes involved in carcinogenesis and metastasis.
• Investigation of berberine's interaction with micro-RNAs and its role in reactive oxygen species regulation.

Main Results:

• Berberine activates p53 and arrests the cell cycle via Cyclin B modulation.
• It exhibits antiproliferative effects by inhibiting AKT, MAP kinase, and IKB kinase.
• BBR affects autophagy (beclin-1), reduces invasion/metastasis (MMP-9/MMP-2), and inhibits AP-1 activity.
• Berberine interferes with carcinogenesis enzymes (e.g., Telomerase, Topoisomerase) and regulates ROS/inflammatory cytokines.
• Interaction with micro-RNAs contributes to its anticancer properties.

Conclusions:

• Berberine demonstrates multifaceted anticancer properties through a wide array of molecular targets.
• Its ability to modulate cell cycle, proliferation, invasion, and carcinogenic pathways makes it a promising anticancer agent.
• Further research and development could establish berberine as a valuable candidate in cancer treatment strategies.